First Patient Dosed in Clinical Trial of IB-T101 for ccRCC
“This is a major milestone for Inceptor Bio as we advance IB-T101 into the clinic,” said Dr. Matthias Schroff, Chief Executive Officer of Inceptor Bio. “Similar to elite athletes training at high elevation, T cells conditioned in challenging environments develop the attributes needed to outperform in solid tumors. With the support and confidence of our investors, we are focused on advancing our lead program with the goal of delivering a best-in-class therapy that has the potential to change the treatment paradigm for patients facing these challenging cancers.”
Share:
More News
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.
“Many solid tumors remain difficult to treat despite advances in immunotherapy,” said Rustam Esanov, CEO and co-founder of Reprogram Biosciences. “Our approach is differentiated by its reprogramming of the tumor itself into a site of immune activation, rather than relying on exogenous immune cells or broadly acting systemic agents.”
Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that the first patient has been dosed in a Phase III clinical trial evaluating its novel Nectin-4-targeting ADC (Bulumtatug Fuvedotin, or BFv, R&D code: 9MW2821) for the treatment of locally advanced or metastatic triple-negative breast cancer (TNBC).